<html>
<body>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:16pt;;"><font style="font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:16pt;;"><font style="font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:16pt;;"><font style="font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d)</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): March 14, 2014</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;">&nbsp;</p><p style="text-align:center;border-bottom:Solid 1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:16pt;;"><font style="font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Portola Pharmaceuticals, Inc.</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:32%; border-bottom:solid 1pt #000000;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</font></p></td>
<td valign="top" style="padding-left:0 pt;padding-Right:0 pt;padding-Top:0 pt;width:2%; border-bottom:solid 1pt transparent;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="padding-left:0 pt;padding-Right:0 pt;padding-Top:0 pt;padding-Bottom:1 pt;width:32%; border-bottom:solid 1pt #000000;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-weight:bold;;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">001-35935</font></a></p></td>
<td valign="top" style="padding-left:0 pt;padding-Right:0 pt;padding-Top:0 pt;width:2%; border-bottom:solid 1pt transparent;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:32%; border-bottom:solid 1pt #000000;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20-0216859</font></p></td>
</tr>
<tr>
<td valign="top" style="width:auto;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</font></p></td>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:auto;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</font></p></td>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:auto;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer Identification No.)</font></p></td>
</tr>
<tr>
<td valign="top" style="width:auto;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</font></p></td>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:auto;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:auto;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
</tr>
</table></div><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:60%; border-bottom:solid 1pt #000000;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-family:;font-weight:bold;;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">270 E. Grand Avenue</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">South San Francisco, California</font></p></td>
<td valign="top" style="padding-left:0 pt;padding-Right:0 pt;padding-Top:0 pt;width:5%; border-bottom:solid 1pt transparent;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="bottom" style="width:35%; border-bottom:solid 1pt #000000;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">94080</font></p></td>
</tr>
<tr>
<td valign="top" style="width:auto;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</font></p></td>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:auto;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</font></p></td>
</tr>
</table></div><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-weight:bold;;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (650) 246-7300</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-weight:bold;;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Wingdings';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:4%;margin-right:0%;text-indent:-4%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Wingdings';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:4%;margin-right:0%;text-indent:-4%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Wingdings';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:4%;margin-right:0%;text-indent:-4%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Wingdings';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="margin-bottom:10pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></font></p><p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;">&nbsp;</p>

<div style="width:100%;"><hr style="page-break-after:always"></div><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-weight:bold;;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 14, 2014 the Board of Directors (the &#8220;Board&#8221;) of Portola Pharmaceuticals, Inc. (the &#8220;Company&#8221;) appointed Mr. John H. Johnson to serve as a director of the Company, effective as of March 26, 2014. The Board also appointed Mr. Johnson to serve on the Compensation Committee. </font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Johnson has served as a member of the Board of Directors of Dendreon Corporation since August 2011, and was named Chair in July 2013. He has also served as the President and Chief Executive Officer of Dendreon Corporation since January 2012. Mr. Johnson previously served as the Chief Executive Officer and a director of Savient Pharmaceuticals, Inc., a pharmaceutical company, from January 2011 until January 2012, and prior to that time, served as Senior Vice President and President of Eli Lilly and Company&#8217;s Oncology unit from November 2009 until January 2011. He was also Chief Executive Officer of ImClone Systems Incorporated (&#8220;ImClone&#8221;), which develops targeted biologic cancer treatments, from August 2007 until November 2009, and served on ImClone&#8217;s Board of Directors until it was acquired by Eli Lilly in November 2008. Prior to joining ImClone, Mr. Johnson served as Company Group Chairman of Johnson &amp; Johnson&#8217;s Worldwide Biopharmaceuticals unit from 2005 until August 2007, President of its Ortho Biotech Products LP and Ortho Biotech Canada unit from 2003 until 2005, and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 until 2003. Prior to joining Johnson &amp; Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corporation and Pfizer, Inc. Mr. Johnson is the former chairman of Tranzyme Pharma, Inc. He is currently a member of the board of directors of Cempra Pharmaceuticals, Inc. and Histogenics Corporation.  He earned his bachelor&#8217;s degree from the East Stroudsburg University of Pennsylvania.</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with his appointment to the Board and the Compensation Committee, Mr. Johnson will receive annual cash compensation of $50,000 and $6,500, respectively. In addition, Mr. Johnson will receive an initial stock option grant to purchase 20,000 shares of Company common stock at an exercise price equal to the fair market value of the common stock on the effective date of his appointment, such grant to vest, subject to continuous service, on a monthly basis for the 36-month period following the date of grant. </font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A copy of the press release announcing Mr. Johnson&#8217;s appointment is attached hereto as Exhibit 99.1.&nbsp;&nbsp;&#160;</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-weight:bold;;font-size:10pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01 Financial Statements and Exhibits</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;Exhibits</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:10.96%; border-bottom:solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</font></p></td>
<td valign="bottom" style="width:2.56%; border-bottom:solid 1pt transparent;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="bottom" style="width:86.48%; border-bottom:solid 1pt #000000;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description&#160;of&#160;Document</font></p></td>
</tr>
<tr>
<td valign="top" style="width:10.96%;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</font></p></td>
<td valign="bottom" style="width:2.56%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:86.48%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Press release entitled &#8220;Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors&#8221; dated March 18, 2014.</font></p></td>
</tr>
</table></div><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:6.67%;font-size:10pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:9pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></font></p><p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;">&nbsp;</p>

<div style="width:100%;"><hr style="page-break-after:always"></div><p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p><p style="margin-bottom:12pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:6.67%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p><div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td colspan="3" valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-weight:bold;;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Portola Pharmaceuticals, Inc.</font></p></td>
</tr>
<tr>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td colspan="3" valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: March 18, 2014</font></p></td>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td colspan="3" valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top" style="width:43.86%; border-bottom:solid 1pt transparent;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:1.92%; border-bottom:solid 1pt transparent;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:3.4%; border-bottom:solid 1pt transparent;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</font></p></td>
<td valign="top" style="width:47.9%; border-bottom:solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> /s/ Mardi C. Dier</font></p></td>
<td valign="top" style="width:2.92%; border-bottom:solid 1pt transparent;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td colspan="2" valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mardi C. Dier</font></p></td>
</tr>
<tr>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-style:italic;;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-style:italic;;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td colspan="2" valign="top" style="width:auto;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President and Chief Financial Officer</font></p></td>
</tr>
</table></div><p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.67%;margin-right:0%;text-indent:1.67%;font-size:11pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;">&nbsp;</p>

<div style="width:100%;"><hr style="page-break-after:always"></div><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT&#160;INDEX</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:9.44%; border-bottom:solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:8pt;"><font style="font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</font></p></td>
<td valign="bottom" style="width:2.56%; border-bottom:solid 1pt transparent;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:1pt;"><font style="font-weight:bold;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="bottom" style="width:88%; border-bottom:solid 1pt #000000;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:8pt;"><font style="font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description&#160;of&#160;Document</font></p></td>
</tr>
<tr>
<td valign="top" style="width:9.44%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</font></p></td>
<td valign="bottom" style="width:2.56%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:1pt;"><font style="font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:88%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Press release entitled &#8220;Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors&#8221; dated March 18, 2014.</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div><p style="margin-bottom:10pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;">&nbsp;</p></body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "ptla-8k_20140314.htm", "description": "FORM 8-K", "secsgml_size_bytes": 38849}]
{"company-data": {"conformed-name": "PORTOLA PHARMACEUTICALS INC", "cik": "0001269021", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35935", "film-number": "14699762"}, "business-address": {"street1": "270 EAST GRAND AVENUE, SUITE 22", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080", "phone": "650-244-6864"}, "mail-address": {"street1": "270 EAST GRAND AVENUE, SUITE 22", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 14, 2014
Portola Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-35935
20-0216859
(State or other jurisdiction
(Commission File Number)
(IRS Employer Identification No.)
of incorporation)
270 E. Grand Avenue
South San Francisco, California
94080
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (650) 246-7300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 14, 2014 the Board of Directors (the "Board") of Portola Pharmaceuticals, Inc. (the "Company") appointed Mr. John H. Johnson to serve as a director of the Company, effective as of March 26, 2014. The Board also appointed Mr. Johnson to serve on the Compensation Committee.
Mr. Johnson has served as a member of the Board of Directors of Dendreon Corporation since August 2011, and was named Chair in July 2013. He has also served as the President and Chief Executive Officer of Dendreon Corporation since January 2012. Mr. Johnson previously served as the Chief Executive Officer and a director of Savient Pharmaceuticals, Inc., a pharmaceutical company, from January 2011 until January 2012, and prior to that time, served as Senior Vice President and President of Eli Lilly and Company's Oncology unit from November 2009 until January 2011. He was also Chief Executive Officer of ImClone Systems Incorporated ("ImClone"), which develops targeted biologic cancer treatments, from August 2007 until November 2009, and served on ImClone's Board of Directors until it was acquired by Eli Lilly in November 2008. Prior to joining ImClone, Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit from 2005 until August 2007, President of its Ortho Biotech Products LP and Ortho Biotech Canada unit from 2003 until 2005, and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 until 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corporation and Pfizer, Inc. Mr. Johnson is the former chairman of Tranzyme Pharma, Inc. He is currently a member of the board of directors of Cempra Pharmaceuticals, Inc. and Histogenics Corporation.  He earned his bachelor's degree from the East Stroudsburg University of Pennsylvania.
In connection with his appointment to the Board and the Compensation Committee, Mr. Johnson will receive annual cash compensation of $50,000 and $6,500, respectively. In addition, Mr. Johnson will receive an initial stock option grant to purchase 20,000 shares of Company common stock at an exercise price equal to the fair market value of the common stock on the effective date of his appointment, such grant to vest, subject to continuous service, on a monthly basis for the 36-month period following the date of grant.
A copy of the press release announcing Mr. Johnson's appointment is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Number
Description of Document
99.1
Press release entitled "Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors" dated March 18, 2014.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Portola Pharmaceuticals, Inc.
Dated: March 18, 2014
By:
/s/ Mardi C. Dier
Mardi C. Dier
Executive Vice President and Chief Financial Officer
EXHIBIT INDEX
Number
Description of Document
99.1
Press release entitled "Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors" dated March 18, 2014.